Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Schering Aktiengesellschaft

The Broad Institute, Inc.

Deutsches Krebsforschungszentrum

Bayer Pharma Aktiengesselschaft

Scnering Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Roland Neuhaus

Hartmut Rehwinkel

Katja Zimmermann

Olaf Panknin

Ulf Bömer

Andrea Hägebarth

Duy Nguyen

William Johnston Scott

Marcus Bauser

Gerhard Siemeister

Lars Bärfacker

Sven Ring

Marcus Koppitz

Sonja Anlauf

Stuart Ince

Holger Siebeneicher

Stefan Kaulfuss

Ulrich Klar

Wolfgang Schwede

Hans Briem

Antje Margret Wengner

Ingo Hartung

Andreas Huth

Dieter Seidelmann

Dirk Kosemund

Eckhard Ottow

Bernd Buchmann

Herbert H Schneider

Ludwig Zorn

Joachim Kuhnke

Norbert Schmees

Andrea Rotgeri

Elisabeth Pook

Lechoslaw Turski

Ulrich Bothe

Martin Kruger

Judith Günther

Steven James Ferrara

Martin Lange

Amaury Ernesto Fernandez-Montalvan

Jens Nagel

Kirstin Petersen

Marion Hitchcock

Christian Stegmann

Nico Bräuer

Stephan Siegel

Thorsten Blume

Adam James Davenport

Stefan Nikolaus Gradl

Sandra Berndt

Antonius Ter Laak

Bernard Jacques Haendler

Reinhard Nubbemeyer

Oliver Politz

Paul Matthew Blaney

Detlev Suelzle

Joseph S Beckman

Oliver Martin Fischer

Simon Anthony Herbert

Holger Steuber

Florian Pühler

Nicole Schmidt

Martin Krüger

Shelley Anne Parrott

Roman Hillig

Daniel Gallenkamp

Daniel Korr

Naomi Barak

Rafael Carretero

Rienk Offringa

Andreas Sutter

Vera Pütter

James Lindsay Carr

Andrea Haegebarth

Michael Brüning

Andreas Von Deimling

Iris Pribilla

Matyas Gorjanacz

Hermann Künzer

Robert James Townsend

Jeffrey Stuart Mowat

Pascale Lejeune

Nina Connelly Ursinyova

Petra Helfrich

Gisbert Depke

Nuria Aiguabella Font

Gabriele Leder

Robin Michael Meier

Léa Aurelie Bouché

Ernesto Amaury Fernandez-Montalvan

Stefan Niklaus Gradl

Craig Strathdee

Jacob Jaffe

Gianna Toschi

Stefan Kaulfuß

Amaury Ernesto Fernandez-montalvan

Jörg Wichard

Robin Meier

Judith Gunther

The present invention provides acyl sulfonamide compounds of general formula (I):

Acyl sulfonamides for treating cancer

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R, R, R, R, R, Rand Rare as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control. 

Substituted pyrrolopyridine-derivatives

The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R, Rand Rare as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients. 

Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors

The present invention relates to compounds of general formula (I): in which R, R, R, R, R, R, R, R, R, R, R, Rand X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Fused imidazoles as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Benzimidazol-2-amines as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I) in which R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors

The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I): in which A, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I) in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors

Benzimidazol-2-amines as MIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to benzimidazol-2-amines of general formula (I): in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R, R, Rand Rhave the meanings given for the general formula (I),to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.

BET protein-inhibiting 5-aryltriazoleazepines

The present invention relates to a method for the treatment of a cancer that is sensitive to Pi3K/Akt pathway inhibition by administering a therapeutically effective amount of a compound of formula (I) 

Imidazopyridazines as Akt kinase inhibitors

The present invention relates to substituted imidazopyridazine compounds of general formula I in which R, Rand A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted imidazopyridazines

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Growing community of inventors

Berlin, Germany

Roland Neuhaus